Ono Pharmaceutical Co LtdEigentümerstruktur
| Preis (2026-07-24) | 52W Hoch | 52W Tief |
| 4.93 USD | 5,426 USD | 3,323 USD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| - USD | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 1.409.862.919 | - | - |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name Ono Pharmaceutical Co Ltd
Mitarbeiter 4.206
Handelsplatz PINK
Ticker Symbol OPHLY
IPO Datum -
Adresse 8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564
Webseite https://www.ono-pharma.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Mr. Gyo Sagara | CEO & Chairman of the Board |
| 2 | Mr. Toichi Takino Ph.D. | President, COO & Representative Director |
| 3 | Mr. Toshihiro Tsujinaka | Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir |
| 4 | Mr. Masaki Ito | Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div. |
| 5 | Takehiro Yamada | Corporate Officer & Head of Risk and Compliance Management Department |
| 6 | Hiromu Habashita Ph.D. | Corporate Officer, Senior Vice President, Discovery & Research |
| 7 | Shinji Takai M.D., Ph.D. | Corporate Officer & Head of Medical Affairs |
| 8 | Satoshi Takahagi | Senior Director of EHS Promotion & Corporate Officer |
| 9 | Akira Takada | Corporate Executive Officer & Executive Director of CMC & Production |
| 10 | Mr. Tatsuya Okamoto | Corporate Officer & Executive Director of Clinical Development, Oncology Clinical Development Div. |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
Für dieses Unternehmen liegen derzeit keine Daten zu institutionellen Investoren vor.